Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Risperidone for Memory and Executive Processes in 22q11.2 Deletion Syndrome
NCT04639960Terminated
- Sponsor
- Université de Genève
- Start
- Sep 2017
- Primary completion
- May 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, double-blind trial in 22q11.2 deletion syndrome (22qDS) comparing Risperidone with Placebo (2 arms). Primary endpoints: Conners' Continuous Performance Test, third edition, Stroop Task Inhibition Ratio and 11 more. Started Sep 2017; status: terminated.
02
Drugs
risperidone
03
Conditions
22q11.2 deletion syndrome (22qDS)
Beyond the preview
Go deeper on NCT04639960.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04639960.